{"search_session":{},"preferences":{"l":"en","queryLanguage":"en"},"patentId":"060-391-678-088-059","frontPageModel":{"patentViewModel":{"ref":{"entityRefType":"PATENT","entityRefId":"060-391-678-088-059"},"entityMetadata":{"linkedIds":{"empty":true},"tags":[],"collections":[{"id":8909,"type":"PATENT","title":"Cornell Univ Patent Portfolio","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":11969,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[{"id":8223,"type":"COLLECTION","user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"text":"
Search applicants and owners= \"Cornell Univ\", \" Univ Cornell\", \" Cornell Res* Found*\", \"Corne* Univ* Tech* Enter* Comm*\".
Select more for logical variant
Add to collection
Select all the results in the collect and expand by simple families
Add to collection
Total patent: 10677
Search applicants and owners= \"Cornell Univ\", \" Univ Cornell\", \" Cornell Res* Found*\", \"Corne* Univ* Tech* Enter* Comm*\".
Select more for logical variant
Add to collection
Select all the results in the collect and expand by simple families
Add to collection
Total patent: 10677
providing a database comprising information relating to protein expression levels associated and not associated with Alzheimer's disease, wherein the database comprises information relating to at least a majority of the following proteins: albumin, alpha-1-antitrypsin, apolipoprotin E, apolipoprotein J, complement component 3, contactin, fibrin beta, Ig heavy chain, Ig light chain, neuronal pentraxin receptor, plasminogen, proSAAS, retinol-binding protein, transthyretin, and vitamin D binding protein;\n
providing information relating to proteins found in one or more cerebrospinal fluid samples from a subject; and\n
using the database to analyze the information from the subject to diagnose the subject's Alzheimer's disease state."],"number":1,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the method is carried out to determine whether the subject has Alzheimer's disease or does not have Alzheimer's disease."],"number":2,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the method is carried out to monitor progression of disease in a subject believed to have Alzheimer's disease."],"number":3,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 3, further comprising:\n
administering a therapeutic substance to the subject as a function of the monitoring of progression of disease in the subject."],"number":4,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the providing a database comprises:\n
obtaining proteomes of cerebrospinal fluid samples collected from subjects diagnosed with Alzheimer's disease;\n
obtaining proteomes of cerebrospinal fluid samples collected from subjects diagnosed as not having Alzheimer's disease;\n
comparing the samples from the subjects with Alzheimer's disease to the samples from the subjects without Alzheimer's disease;\n
characterizing the samples and generating data based on the characterization; and\n
analyzing the data to identify one or more proteins useful in assisting in the diagnosis of Alzheimer's disease."],"number":5,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 5, wherein the proteomes of cerebrospinal fluid samples collected from subjects diagnosed with Alzheimer's disease are proteomes of antemortem cerebrospinal fluid samples."],"number":6,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 5, wherein the proteomes of cerebrospinal fluid samples collected from subjects diagnosed as not having Alzheimer's disease are proteomes of antemortem cerebrospinal fluid samples."],"number":7,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 5, wherein the characterizing the cerebrospinal fluid samples is conducted using two-dimensional gel electrophoresis, immunoassays, antibodies, or aptamers for the proteins as well as isoforms and fragments thereof and other comigrating proteins, isoforms, and fragments thereof."],"number":8,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 5, wherein the analyzing the data is conducted using the random forest method."],"number":9,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 5, wherein the proteins are identified by mass spectrometry."],"number":10,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 5, wherein the number of proteomes collected is statistically significant."],"number":11,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the database comprises information relating to isoforms and fragments of the proteins and other comigrating proteins, isoforms, and fragments thereof."],"number":12,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the information relating to at least a majority of proteins further includes proteins involved in beta-amyloid transport, proteins involved in inflammation and/or immune response, proteins that are proteolytic enzyme inhibitors, and proteins that are neuronal membrane proteins."],"number":13,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 13, wherein the database comprises information relating to isoforms and fragments of the proteins and other comigrating proteins, isoforms, and fragments thereof."],"number":14,"annotation":false,"title":false,"claim":true},{"lines":["A computer readable medium having stored thereon programmed instructions for diagnosing a subject's Alzheimer's disease state comprising machine executable code which when executed by at least one processor, causes the processor to perform steps comprising:\n
providing a database comprising information relating to protein expression levels associated and not associated with the Alzheimer's disease, wherein the database comprises information relating to at least a majority of the following proteins: albumin, alpha-1-antitrypsin, apolipoprotin E, apolipoprotein J, complement component 3, contactin, fibrin beta, Ig heavy chain, Ig light chain, neuronal pentraxin receptor, plasminogen, proSAAS, retinol-binding protein, transthyretin, and vitamin D binding protein;\n
providing information relating to proteins found in one or more cerebrospinal fluid samples from a subject; and\n
using the database to analyze the information from the subject to diagnose the subject's Alzheimer's disease state."],"number":15,"annotation":false,"title":false,"claim":true},{"lines":["The medium of claim 15, wherein the providing a database comprises:\n
obtaining proteomes of cerebrospinal fluid samples collected from subjects diagnosed with Alzheimer's disease;\n
obtaining proteomes of cerebrospinal fluid samples collected from subjects diagnosed as not having Alzheimer's disease;\n
comparing the samples from the subjects with Alzheimer's disease to the samples from the subject without Alzheimer's disease;\n
characterizing the samples and generating data based on the characterization; and\n
analyzing the data to identify one or more proteins useful in assisting in the diagnosis of Alzheimer's disease."],"number":16,"annotation":false,"title":false,"claim":true},{"lines":["The medium of claim 16, wherein the proteomes of cerebrospinal fluid samples collected from subjects diagnosed with Alzheimer's disease are proteomes of antemortem cerebrospinal fluid samples."],"number":17,"annotation":false,"title":false,"claim":true},{"lines":["The medium of claim 16, wherein the proteomes of cerebrospinal fluid samples collected from subjects diagnosed as not having Alzheimer's disease are proteomes of antemortem cerebrospinal fluid samples."],"number":18,"annotation":false,"title":false,"claim":true},{"lines":["The medium of claim 16, wherein the characterizing the cerebrospinal fluid samples is conducted using two-dimensional gel electrophoresis, immunoassays, antibodies, or aptamers for the proteins as well as isoforms and fragments thereof and other comigrating proteins, isoforms, and fragments thereof."],"number":19,"annotation":false,"title":false,"claim":true},{"lines":["The medium of claim 16, wherein the analyzing the data is conducted using the random forest medium."],"number":20,"annotation":false,"title":false,"claim":true},{"lines":["The medium of claim 16, wherein the proteins are identified by mass spectrometry."],"number":21,"annotation":false,"title":false,"claim":true},{"lines":["The medium of claim 16, wherein the number of proteomes collected is statistically significant."],"number":22,"annotation":false,"title":false,"claim":true},{"lines":["The medium of claim 15, wherein the database comprises information relating to isoforms and fragments of the proteins and other comigrating proteins, isoforms, and fragments thereof."],"number":23,"annotation":false,"title":false,"claim":true},{"lines":["A system for diagnosing a subject's Alzheimer's disease state, the system comprising:\n
a storage system with at least one database comprising information relating to protein expression levels associated and not associated with Alzheimer's disease, wherein the database comprises information relating to at least a majority of the following proteins: albumin, alpha-1-antitrypsin, apolipoprotin E, apolipoprotein J, complement component 3, contactin, fibrin beta, Ig heavy chain, Ig light chain, neuronal pentraxin receptor, plasminogen, proSAAS, retinol-binding protein, transthyretin, and vitamin D binding protein; and\n
a diagnostic processing system that receives information relating to proteins found in one or more cerebrospinal fluid samples from a subject and uses the database in the storage system to analyze the information from the subject to diagnose the subject's Alzheimer's disease state."],"number":24,"annotation":false,"title":false,"claim":true},{"lines":["The system of claim 24 further comprising a database compilation processing system that obtains proteomes of cerebrospinal fluid samples collected from subjects diagnosed with Alzheimer's disease, obtains proteomes of cerebrospinal fluid samples collected from subjects diagnosed as not having Alzheimer's disease, compares the samples from the subjects with Alzheimer's disease to the samples from the subjects not having Alzheimer's disease, characterizes the samples and generates data based on the characterization, and analyzes the data to identify one or more proteins useful in assisting in the diagnosis of Alzheimer's disease to generate the database."],"number":25,"annotation":false,"title":false,"claim":true},{"lines":["The system of claim 25, wherein the proteomes of cerebrospinal fluid samples collected from subjects diagnosed with Alzheimer's disease are proteomes of antemortem cerebrospinal fluid samples."],"number":26,"annotation":false,"title":false,"claim":true},{"lines":["The system of claim 25, wherein the proteomes of cerebrospinal fluid samples collected from subjects diagnosed as not having Alzheimer's disease are proteomes of antemortem cerebrospinal fluid samples."],"number":27,"annotation":false,"title":false,"claim":true},{"lines":["The system of claim 25, wherein the database compilation processing system characterizes the cerebrospinal fluid samples using two-dimensional gel electrophoresis, immunoassays, antibodies, or aptamers for the proteins as well as isoforms and fragments thereof and other comigrating proteins, isoforms, and fragments thereof."],"number":28,"annotation":false,"title":false,"claim":true},{"lines":["The system of claim 25, wherein the database compilation processing system analyzes the data using the random forest system."],"number":29,"annotation":false,"title":false,"claim":true},{"lines":["The system of claim 25, wherein the proteins are identified by mass spectrometry."],"number":30,"annotation":false,"title":false,"claim":true},{"lines":["The system of claim 25, wherein the number of proteomes collected is statistically significant."],"number":31,"annotation":false,"title":false,"claim":true},{"lines":["The system of claim 24, wherein the database comprises information relating to isoforms and fragments of the proteins and other comigrating proteins, isoforms, and fragments thereof."],"number":32,"annotation":false,"title":false,"claim":true}]}},"filters":{"npl":[],"notNpl":[],"applicant":[],"notApplicant":[],"inventor":[],"notInventor":[],"owner":[],"notOwner":[],"tags":[],"dates":[],"types":[],"notTypes":[],"j":[],"notJ":[],"fj":[],"notFj":[],"classIpcr":[],"notClassIpcr":[],"classNat":[],"notClassNat":[],"classCpc":[],"notClassCpc":[],"so":[],"notSo":[],"sat":[]},"sequenceFilters":{"s":"SEQIDNO","d":"ASCENDING","p":0,"n":10,"sp":[],"si":[],"len":[],"t":[],"loc":[]}}